Kineta Inc (KA)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Richard Peters
Employees:
40
219 TERRY AVE. N., SUITE 300, SEATTLE, WA, 98109
(206) 378-0400

Yumanity Therapeutics Inc. engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein.

Data derived from most recent annual or quarterly report
Market Cap 42.496 Million Shares Outstanding9.769 Million Avg 30-day Volume 14.662 Thousand
P/E Ratio0.0 Dividend Yield42.0588 EPS-1.14
Price to Revenue6.7312 Debt to Equity0.2825 EBITDA-56.289 Million
Price to Book Value14.7049 Operating Margin-648.7097 Enterprise Value33.338 Million
Current Ratio1.03 EPS Growth-2.218 Quick Ratio0.993
1 Yr BETA 1.7619 52-week High/Low 9.0 / 0.29 Profit Margin-984.1289
Operating Cash Flow Growth-281.9168 Free Cash Flow to Firm (FCFF) TTM -26.006 Million Free Cash Flow to Equity (FCFE) TTM-25.46 Million
Altman Z-Score-35.0558
View SEC Filings from KA instead.

View recent insider trading info

Kineta Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding KA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding KA

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-11-30 by IADONATO SHAWN
  • 4: filed on 2023-10-12 by FOOTE MARION R
  • 4: filed on 2023-09-21 by KENNY PAULINE
  • 4: filed on 2023-09-21 by IADONATO SHAWN
  • 4: filed on 2023-09-21 by BARTOSZEK RAYMOND J.
  • 4: filed on 2023-09-19 by BAKER KEITH
  • 4: filed on 2023-09-19 by BARTOSZEK RAYMOND J.
  • 4: filed on 2023-09-15 by GUILLAUDEUX THIERRY
  • 4: filed on 2023-07-05 by DYLLA SCOTT J.
  • 3: filed on 2023-07-05 by DYLLA SCOTT J.

    • Events (8k)

  • 8-K: filed on 2023-11-06:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-11-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-11-03:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-10-17:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-10-05:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-10-04:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-10-03:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-31:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-16:
    Item 8.01: Other Events
  • 8-K: filed on 2023-08-11:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    8 Thousand total shares from 3 transactions

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    4.4 Thousand total shares from 1 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    PHILIPS CRAIG W. PRESIDENT

    • Officer
    		 95,465 2023-11-28 7

    IADONATO SHAWN CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 1,354,913 2023-11-28 7

    FOOTE MARION R

    • Director
    		 143,204 2023-10-11 4

    KENNY PAULINE GENERAL COUNSEL & SECRETARY

    • Officer
    		 18,448 2023-09-20 6

    BARTOSZEK RAYMOND J.

    • Director
    		 861,435 2023-09-19 7

    BAKER KEITH CHIEF FINANCIAL OFFICER

    • Officer
    		 16,880 2023-09-18 5

    GUILLAUDEUX THIERRY CHIEF SCIENTIFIC OFFICER

    • Officer
    		 21,696 2023-09-14 4

    DRAPKIN KIMBERLEE C

    • Director
    		 0 2023-07-01 2

    DYLLA SCOTT J.

    • Director
    		 0 2023-07-01 2

    ARKOWITZ DAVID

    • Director
    		 0 2023-04-12 1

    PETERS RICHARD

    • Director
    		 0 2023-04-12 2

    SMITH DEVIN WHITTEMORE SVP AND GENERAL COUNSEL

    • Officer
    		 13,961 2022-12-02 0

    EPSTEIN MARIE PRINCIPAL ACCOUNTING OFFICER

    • Officer
    		 8,883 2022-12-02 0

    WYZGA MICHAEL D SEE REMARKS

    • Officer
    		 13,997 2022-12-02 0

    MOHSEN PAULASH CHIEF BUSINESS OFFICER

    • Officer
    		 59,135 2022-02-03 0

    VERMA AJAY EVP, HEAD OF R&D

    • Officer
    		 5,000 2021-11-11 0

    PICKETT CECIL B

    • Director
    		 14,800 2021-06-02 0

    ALLEN PATRICIA L

    • Director
    		 14,800 2021-06-02 0

    HEYMAN RICHARD A.

    • Director
    		 14,800 2021-06-02 0

    KELLY JEFFERY W.

    • Director
    		 14,800 2021-06-02 0

    ZYDOWSKY LYNNE

    • Director
    		 14,800 2021-06-02 0

    COLES N ANTHONY EXECUTIVE CHAIR

    • Officer
    • Director
    		 78,650 2021-04-01 0

    ROBERTSON BRIGITTE CHIEF MEDICAL OFFICER

    • Officer
    		 0 2021-02-01 0

    BERGER FRANKLIN M

    • Director
    		 0 2020-06-29 0

    DULAC EMMANUEL

    • Director
    		 0 2020-06-29 0

    CHOWDHURY BADRUL A.

    • Director
    		 0 2020-06-29 0

    ALFIERI MICHAEL INTERIM HEAD OF FINANCE

    • Officer
    		 0 2020-05-12 0

    CHHABRA MEENU PRESIDENT AND CEO

    • Officer
    • Director
    		 0 2020-03-02 0

    MUNOZ BENITO CHIEF SCIENTIFIC OFFICER

    • Officer
    		 0 2020-03-02 0

    LARSON ERIC D SEE REMARKS

    • Officer
    		 0 2020-03-02 0

    GILMARTIN GEOFFREY S. CHIEF MEDICAL OFFICER

    • Officer
    		 0 2020-03-02 0

    ZECEVIC MARIJA CHIEF COMMERCIAL OFFICER

    • Officer
    		 0 2020-03-02 0

    WILSON SHEILA CHIEF OPERATING OFFICER

    • Officer
    		 0 2020-03-02 0

    NEW ENTERPRISE ASSOCIATES 12, LIMITED PARTNERSHIP

    NEA PARTNERS 12, LIMITED PARTNERSHIP

    NEA 12 GP, LLC

    BARRIS PETER J

    BASKETT FOREST

    KERINS PATRICK J

    SANDELL SCOTT D

    • 10% Owner
    		 No longer subject to file 2019-11-26 0

    LEE PO SHUN SEE REMARKS

    • Officer
    		 0 2019-03-01 0

    ZIMMERMAN SANDRA M. SEE REMARKS

    • Officer
    		 0 2018-08-06 0

    BARRETT M JAMES

    • Director
    • 10% Owner
    		 0 2018-06-15 0

    RABINOWITZ ERIC

    • Director
    		 0 2018-06-15 0

    BOUDREAU HELEN M CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2018-03-01 0

    CORMORANT ASSET MANAGEMENT, LLC

    CHEN BIHUA

    CORMORANT GLOBAL HEALTHCARE GP, LLC

    CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP

    • Director
    • 10% Owner
    		 No longer subject to file 2017-12-14 0

    HAGEN BRETT R SEE REMARKS

    • Officer
    		 0 2017-04-03 0

    FMR LLC

    • SEE REMARK 1
    		 No longer subject to file 2017-03-13 0

    NEW ENTERPRISE ASSOCIATES 12, LIMITED PARTNERSHIP

    NEA PARTNERS 12, LIMITED PARTNERSHIP

    NEA 12 GP, LLC

    BARRIS PETER J

    BASKETT FOREST

    KERINS PATRICK J

    KOLLURI KRISHNA KITTU

    SANDELL SCOTT D

    • 10% Owner
    		 3,554,610 2016-09-14 0

    DETORE JAMES M. SEE REMARKS

    • Officer
    		 0 2016-08-04 0

    MIRABELLI CHRISTOPHER

    HEALTHCARE VENTURES VIII, L.P.

    CAVANAUGH JAMES H

    HEALTHCARE PARTNERS VIII, LLC

    HEALTHCARE PARTNERS VIII, L.P.

    LAWLOR AUGUSTINE

    LITTLECHILD JOHN W

    WERNER HAROLD R

    • Director
    • 10% Owner
    		 2,164,095 2016-02-17 0

    NOVARTIS BIOVENTURES LTD

    NOVARTIS AG

    • 10% Owner
    		 No longer subject to file 2016-02-17 0

    PERRIGO CO PLC

    PERRIGO HOLDINGS LTD.

    ELAN PHARMA INTERNATIONAL LTD.

    PERRIGO CORP LTD.

    PERRIGO SCIENCE ONE LTD.

    • 10% Owner
    		 2,908,067 2016-02-10 0

    WALSH CHRISTOPHER T PHD

    • Director
    		 6,012 2016-02-10 0

    THIBAULT LANCE E SEE REMARKS

    • Officer
    		 0 2016-02-10 0

    MIRABELLI CHRISTOPHER

    • Director
    • 10% Owner
    		 0 2016-02-10 0

    ELAN SCIENCE ONE LTD

    • 10% Owner
    		 0 2016-02-10 0

    MIRZAC ROMEO PRINCIPAL ACCOUNTING OFFICER

    • Officer
    		 0 2016-02-10 0

    SMART JANET L SEE REMARKS

    • Officer
    		 0 2016-02-10 0

    WALSHE CONOR M

    • Director
    		 0 2016-02-10 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    IADONATO SHAWN - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-11-30 17:21:22 -0500 2023-11-29 P 4,100 $3.51 a 675,230 direct 4.3902 4.3902 2 0.0 1

    IADONATO SHAWN - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-11-30 17:21:22 -0500 2023-11-28 P 900 $3.33 a 671,130 direct 4.3902 4.3902 2 0.0 1

    PHILIPS CRAIG W. - Officer PRESIDENT

    		2023-11-30 17:27:11 -0500 2023-11-28 P 3,000 $3.27 a 60,811 direct 4.3902 4.3902 2 0.0 1

    FOOTE MARION R - Director

    		2023-10-12 16:25:50 -0400 2023-10-11 M 4,443 $0.14 a 143,204 direct 0.0 0.8287 -14.3646 22.0994 17 -14.3646 31

    FOOTE MARION R - Director

    		2023-10-12 16:25:50 -0400 2023-10-11 M 4,443 d 0 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    KINETA INC KA 2023-12-06 19:45:04 UTC -11.9357 17.2557 550000
    KINETA INC KA 2023-12-06 19:15:04 UTC -11.9357 17.2557 550000
    KINETA INC KA 2023-12-06 18:45:03 UTC -11.9357 17.2557 550000
    KINETA INC KA 2023-12-06 18:15:03 UTC -11.9357 17.2557 550000
    KINETA INC KA 2023-12-06 17:45:03 UTC -11.9357 17.2557 550000
    KINETA INC KA 2023-12-06 17:15:04 UTC -11.9357 17.2557 550000
    KINETA INC KA 2023-12-06 16:45:04 UTC -11.9357 17.2557 550000
    KINETA INC KA 2023-12-06 16:15:04 UTC -11.9357 17.2557 550000
    KINETA INC KA 2023-12-06 15:45:03 UTC -11.9357 17.2557 550000
    KINETA INC KA 2023-12-06 15:15:04 UTC -11.9357 17.2557 550000
    KINETA INC KA 2023-12-06 14:45:04 UTC -11.9357 17.2557 550000
    KINETA INC KA 2023-12-06 14:15:04 UTC -11.9357 17.2557 550000
    KINETA INC KA 2023-12-06 13:45:04 UTC -12.2694 17.5894 550000
    KINETA INC KA 2023-12-06 13:15:04 UTC -12.2694 17.5894 550000
    KINETA INC KA 2023-12-05 22:15:04 UTC -12.2694 17.5894 600000
    KINETA INC KA 2023-12-05 21:45:04 UTC -12.2694 17.5894 600000
    KINETA INC KA 2023-12-05 21:15:04 UTC -12.2694 17.5894 600000
    KINETA INC KA 2023-12-05 20:45:04 UTC -12.2694 17.5894 600000
    KINETA INC KA 2023-12-05 20:15:04 UTC -12.2694 17.5894 600000
    KINETA INC KA 2023-12-05 19:45:04 UTC -12.2694 17.5894 600000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments